
Transforming I&I Treatment with Next-Generation Bispecific Antibodies
Bambusa Therapeutics is developing next-generation bispecific antibodies for immunological and inflammatory (I&I) disorders, targeting conditions like atopic dermatitis, asthma, and COPD. The company's lead programs BBT001 and BBT002 use dual-pathway engineering to address the $40B+ Type 2 inflammatory dermatology market and the $80B+ Type 2 disorder market. Headquartered in Boston's Seaport district, Bambusa is backed by RA Capital, Janus Henderson, Redmile Group, and other leading life science investors.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account